[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635496":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":35,"centralContacts":39,"locations":47,"responsibleParty":80,"collaborators":82,"id":85,"slug":27,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":27,"eligibilityCriteria":90,"healthyVolunteers":86,"sex":91,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":27,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":50,"whyStopped":27,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Alnylam Pharmaceuticals","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"ALN-AGT1 RVR","EXPERIMENTAL","Participants will be administered a single dose of zilebesiran followed by a single dose of ALN-AGT01 RVR.",[13,14],"Drug: ALN-AGT01 RVR","Drug: Zilebesiran",{"label":16,"type":17,"description":18,"interventionNames":19},"Placebo","PLACEBO_COMPARATOR","Participants will be administered a single dose of zilebesiran followed by a single dose of placebo.",[20,14],"Drug: Placebo",[22,28,31],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","ALN-AGT01 RVR","ALN-AGT01 RVR will be administered subcutaneously (SC)",[9],null,{"type":23,"name":16,"description":29,"armGroupLabels":30,"otherNames":27},"Placebo will be administered SC",[16],{"type":23,"name":32,"description":33,"armGroupLabels":34,"otherNames":27},"Zilebesiran","Zilebesiran will be administered SC",[9,16],[36],{"name":37,"affiliation":5,"role":38},"Medical Director","STUDY_DIRECTOR",[40,45],{"name":41,"role":42,"phone":43,"phoneExt":27,"email":44},"Alnylam Clinical Trial Information Line","CONTACT","1-877-ALNYLAM","clinicaltrials@alnylam.com",{"name":41,"role":42,"phone":46,"phoneExt":27,"email":44},"1-877-256-9526",[48,62,71],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":27},"Clinical Trial Site","RECRUITING","Lake Forest","California","92630","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-117.68922,33.64697,{"lat":60,"lon":59},{"facility":49,"status":50,"city":63,"state":64,"zip":65,"country":54,"countryCode":55,"cosmosGeoPoint":66,"geoPoint":70,"contacts":27},"Tampa","Florida","33613",{"type":57,"coordinates":67},[68,69],-82.45843,27.94752,{"lat":69,"lon":68},{"facility":49,"status":50,"city":72,"state":73,"zip":74,"country":54,"countryCode":55,"cosmosGeoPoint":75,"geoPoint":79,"contacts":27},"Savannah","Georgia","31405",{"type":57,"coordinates":76},[77,78],-81.09983,32.08354,{"lat":78,"lon":77},{"type":81,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR",[83],{"name":84,"class":6},"Hoffmann-La Roche","100635496",false,"NCT07553442","A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran","A Phase 2, Randomized, Double-blind, Placebo-controlled, Single Dose Study of the Efficacy, Pharmacodynamics, and Safety of ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran","Part A: Inclusion Criteria\n\n* Is an adult participant with a mean seated office systolic blood pressure (SBP) of at least 130 mmHg and no more than than 170 mmHg\n* Either not taking antihypertensive medication or on stable therapy with up to 2 antihypertensive medications\n\nPart B: Inclusion Criteria\n\n* Is an adult participant with a mean seated office SBP of at least 140 mmHg and no more than 170 mmHg\n* Has discontinued all prior antihypertensive medication other than a calcium channel blocker (CCB) and\u002For thiazide\u002Fthiazide-like diuretic (if taking) for at least 3 weeks\n\nBoth Parts: Exclusion Criteria\n\n* Has known secondary hypertension or serum potassium more than 5 mmol\u002FL\n* Has an estimated glomerular filtration rate (eGFR) less than 30 mL\u002Fmin\u002F1.73m\\^2\n\nNote: other protocol defined inclusion \u002F exclusion criteria apply","ALL","18 Years","75 Years",{"count":95,"type":96},93,"ESTIMATED","INTERVENTIONAL",[99],"PHASE2","The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.",[102],"Hypertension",[104,105,106,32,107],"RNAi therapeutic","oligonucleotide","Reversir","ALN-AGT01","2026-06-10",{"date":110,"type":111},"2026-06-12","ACTUAL",{"date":113,"type":111},"2026-04-27",{"date":115,"type":96},"2028-10-01",{"name":5,"class":6},3]